Knights of Columbus Asset Advisors LLC Reduces Position in Boston Scientific Corporation $BSX

Key Points

• Knights of Columbus Asset Advisors cut its Boston Scientific stake by 65.8% in the fourth quarter, selling 44,543 shares and ending with 23,158 shares worth about $2.21 million.
• Insiders were buying despite the pullback: directors Cheryl Pegus and David C. Habiger both purchased shares, and insiders bought a total of 9,800 shares over the last three months.
• Boston Scientific reported solid quarterly results, beating EPS and revenue estimates, but the stock was down 2.7% and some analysts trimmed price targets or downgraded the name amid concerns about WATCHMAN and electrophysiology growth.

Knights of Columbus Asset Advisors LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 65.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,158 shares of the medical equipment provider's stock after selling 44,543 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Boston Scientific were worth $2,208,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Claret Asset Management Corp increased its position in shares of Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock valued at $234,000 after acquiring an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC raised its stake in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock worth $206,000 after acquiring an additional 103 shares during the last quarter. Outfitters Financial LLC lifted its position in Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock worth $2,291,000 after acquiring an additional 110 shares during the period. Fayez Sarofim & Co grew its stake in Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider's stock valued at $520,000 after purchasing an additional 111 shares during the last quarter. Finally, Natural Investments LLC grew its stake in Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider's stock valued at $384,000 after purchasing an additional 112 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other news, Director Cheryl Pegus acquired 1,770 shares of the business's stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company's stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 in the last three months. Company insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BSX shares. Truist Financial reduced their price objective on Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, April 23rd. Daiwa Securities Group lowered Boston Scientific from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. Leerink Partners cut their price target on shares of Boston Scientific from $87.00 to $74.00 and set an "outperform" rating on the stock in a report on Thursday. UBS Group decreased their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research note on Tuesday, March 17th. Finally, The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $87.46.

Boston Scientific Stock Down 2.7%

Boston Scientific stock opened at $49.12 on Friday. The business's 50-day moving average price is $60.69 and its 200 day moving average price is $78.84. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm has a market cap of $73.01 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62. Boston Scientific Corporation has a 52 week low of $48.41 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific's revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.